Arcus Biosciences, Inc.
Arcus Biosciences is a global biopharmaceutical company founded in 2015, focused on developing best-in-class molecules and combination therapies for cancer. The company leverages well-characterized biologic pathways to create innovative treatments, emphasizing discovery, accelerated development, and partnerships with the cancer community to bring new medicines to patients faster. Their mission is to combine expertise in science and medicine to pursue cures for cancer.
Industries
Nr. of Employees
medium (51-250)
Arcus Biosciences, Inc.
Patents
Products
Fc-silent anti-TIGIT monoclonal antibody (investigational)
A monoclonal antibody engineered to block TIGIT while minimizing Fc-mediated effector functions, developed for combination use with other immunotherapies.
HIF-2α small-molecule inhibitor (investigational)
A small-molecule antagonist targeting HIF-2α designed to disrupt protein interactions that drive tumor growth, developed with properties suitable for combination therapy in renal cell carcinoma.
A2A/A2B adenosine receptor antagonist (investigational)
A small-molecule adenosine receptor antagonist designed to inhibit multiple adenosine receptor subtypes in the tumor microenvironment to reverse adenosine-mediated immunosuppression and enhance anti-tumor immune responses.
Additional investigational oncology candidates (antibody and small-molecule classes)
Pipeline includes biologics and small molecules such as anti-CD39 biologics, tyrosine kinase inhibitors and anti–PD-1 antibodies developed for use as backbone or combination partners in clinical studies.
Fc-silent anti-TIGIT monoclonal antibody (investigational)
A monoclonal antibody engineered to block TIGIT while minimizing Fc-mediated effector functions, developed for combination use with other immunotherapies.
HIF-2α small-molecule inhibitor (investigational)
A small-molecule antagonist targeting HIF-2α designed to disrupt protein interactions that drive tumor growth, developed with properties suitable for combination therapy in renal cell carcinoma.
A2A/A2B adenosine receptor antagonist (investigational)
A small-molecule adenosine receptor antagonist designed to inhibit multiple adenosine receptor subtypes in the tumor microenvironment to reverse adenosine-mediated immunosuppression and enhance anti-tumor immune responses.
Additional investigational oncology candidates (antibody and small-molecule classes)
Pipeline includes biologics and small molecules such as anti-CD39 biologics, tyrosine kinase inhibitors and anti–PD-1 antibodies developed for use as backbone or combination partners in clinical studies.
Services
Design and operate multi-arm adaptive clinical trials to evaluate multiple investigational combinations and rapidly identify signals of efficacy and safety.
Partnering for discovery-to-clinic programs, including joint development of small molecules and biologics optimized for combination regimens.
Design and implementation of biomarker-informed translational plans to guide patient selection, combination choices and endpoint selection across clinical studies.
Design and operate multi-arm adaptive clinical trials to evaluate multiple investigational combinations and rapidly identify signals of efficacy and safety.
Partnering for discovery-to-clinic programs, including joint development of small molecules and biologics optimized for combination regimens.
Design and implementation of biomarker-informed translational plans to guide patient selection, combination choices and endpoint selection across clinical studies.
Expertise Areas
- Combination therapy development
- Small-molecule discovery and medicinal chemistry
- Antibody therapeutic engineering and Fc modulation
- Translational medicine and biomarker-driven patient selection
Key Technologies
- Medicinal chemistry
- Antibody Fc engineering
- Adenosine pathway targeting (CD73 inhibitors, A2A/A2B antagonists)
- HIF-2α small-molecule inhibition
News & Updates
Arcus employees brought their children to work for a morning of fun science activities and a service project to encourage children fighting cancer, including filling JoyJars and creating Care Cards.
An editorial discussing the need for innovative approaches to treat metastatic kidney cancer, highlighting the progress and ongoing clinical trials involving combination therapies targeting biological pathways such as HIF-2α, tyrosine kinases, and immune checkpoints.
An article about developing molecules that block HIF-2α to improve cancer treatment outcomes, including the design, preclinical testing, and clinical trials of casdatifan, a HIF-2α inhibitor.
A detailed discussion on targeting the adenosine axis in cancer, including molecules like etrumadenant that inhibit adenosine receptors A2aR and A2bR, and their potential to enhance immune response against tumors.
An exploration of Fc-silent anti-TIGIT antibodies, their design, mechanism, and clinical development, aiming to improve immunotherapy combinations for cancer.
An article on how cancer biology guides the study of combination medicines, with a focus on innovative trial designs like platform trials to accelerate drug development.
Arcus employees brought their children to work for a morning of fun science activities and a service project to encourage children fighting cancer, including filling JoyJars and creating Care Cards.
An editorial discussing the need for innovative approaches to treat metastatic kidney cancer, highlighting the progress and ongoing clinical trials involving combination therapies targeting biological pathways such as HIF-2α, tyrosine kinases, and immune checkpoints.
An article about developing molecules that block HIF-2α to improve cancer treatment outcomes, including the design, preclinical testing, and clinical trials of casdatifan, a HIF-2α inhibitor.
A detailed discussion on targeting the adenosine axis in cancer, including molecules like etrumadenant that inhibit adenosine receptors A2aR and A2bR, and their potential to enhance immune response against tumors.
An exploration of Fc-silent anti-TIGIT antibodies, their design, mechanism, and clinical development, aiming to improve immunotherapy combinations for cancer.
An article on how cancer biology guides the study of combination medicines, with a focus on innovative trial designs like platform trials to accelerate drug development.